These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

221 related items for PubMed ID: 26195514

  • 1. Antimicrobial Activity of Fosfomycin-Tobramycin Combination against Pseudomonas aeruginosa Isolates Assessed by Time-Kill Assays and Mutant Prevention Concentrations.
    Díez-Aguilar M, Morosini MI, Tedim AP, Rodríguez I, Aktaş Z, Cantón R.
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6039-45. PubMed ID: 26195514
    [Abstract] [Full Text] [Related]

  • 2. Antimicrobial activity of fosfomycin and tobramycin in combination against cystic fibrosis pathogens under aerobic and anaerobic conditions.
    McCaughey G, McKevitt M, Elborn JS, Tunney MM.
    J Cyst Fibros; 2012 May; 11(3):163-72. PubMed ID: 22138067
    [Abstract] [Full Text] [Related]

  • 3. Use of Calgary and Microfluidic BioFlux Systems To Test the Activity of Fosfomycin and Tobramycin Alone and in Combination against Cystic Fibrosis Pseudomonas aeruginosa Biofilms.
    Díez-Aguilar M, Morosini MI, Köksal E, Oliver A, Ekkelenkamp M, Cantón R.
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084746
    [Abstract] [Full Text] [Related]

  • 4. Resistance development of cystic fibrosis respiratory pathogens when exposed to fosfomycin and tobramycin alone and in combination under aerobic and anaerobic conditions.
    McCaughey G, Diamond P, Elborn JS, McKevitt M, Tunney MM.
    PLoS One; 2013 Jan; 8(7):e69763. PubMed ID: 23936095
    [Abstract] [Full Text] [Related]

  • 5. Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of Pseudomonas aeruginosa, but do not suppress the emergence of fosfomycin resistance.
    Walsh CC, Landersdorfer CB, McIntosh MP, Peleg AY, Hirsch EB, Kirkpatrick CM, Bergen PJ.
    J Antimicrob Chemother; 2016 Aug; 71(8):2218-29. PubMed ID: 27118778
    [Abstract] [Full Text] [Related]

  • 6. Validation of the mutant selection window hypothesis with fosfomycin against Escherichia coli and Pseudomonas aeruginosa: an in vitro and in vivo comparative study.
    Pan AJ, Mei Q, Ye Y, Li HR, Liu B, Li JB.
    J Antibiot (Tokyo); 2017 Feb; 70(2):166-173. PubMed ID: 27756910
    [Abstract] [Full Text] [Related]

  • 7. Antimicrobial activity of tobramycin against respiratory cystic fibrosis Pseudomonas aeruginosa isolates from Bulgaria.
    Strateva T, Petrova G, Mitov I.
    J Chemother; 2010 Dec; 22(6):378-83. PubMed ID: 21303744
    [Abstract] [Full Text] [Related]

  • 8. Fosfomycin and tobramycin in combination downregulate nitrate reductase genes narG and narH, resulting in increased activity against Pseudomonas aeruginosa under anaerobic conditions.
    McCaughey G, Gilpin DF, Schneiders T, Hoffman LR, McKevitt M, Elborn JS, Tunney MM.
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5406-14. PubMed ID: 23959314
    [Abstract] [Full Text] [Related]

  • 9. [Combined application of ciprofloxacin and tobramycin on mutant selective windows of ciprofloxacin against Pseudomonas aeruginosa].
    Liu MT, Sheng MY, Zhang Y, Li Y.
    Zhonghua Yi Xue Za Zhi; 2011 May 31; 91(20):1427-31. PubMed ID: 21756818
    [Abstract] [Full Text] [Related]

  • 10. In vitro activity of fosfomycin in combination with colistin against clinical isolates of carbapenem-resistant Pseudomas aeruginosa.
    Di X, Wang R, Liu B, Zhang X, Ni W, Wang J, Liang B, Cai Y, Liu Y.
    J Antibiot (Tokyo); 2015 Sep 31; 68(9):551-5. PubMed ID: 25805069
    [Abstract] [Full Text] [Related]

  • 11. Fosfomycin enhances the active transport of tobramycin in Pseudomonas aeruginosa.
    MacLeod DL, Velayudhan J, Kenney TF, Therrien JH, Sutherland JL, Barker LM, Baker WR.
    Antimicrob Agents Chemother; 2012 Mar 31; 56(3):1529-38. PubMed ID: 22232284
    [Abstract] [Full Text] [Related]

  • 12. Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis.
    MacLeod DL, Barker LM, Sutherland JL, Moss SC, Gurgel JL, Kenney TF, Burns JL, Baker WR.
    J Antimicrob Chemother; 2009 Oct 31; 64(4):829-36. PubMed ID: 19679597
    [Abstract] [Full Text] [Related]

  • 13. Prevalence of in vitro synergistic antibiotic interaction between fosfomycin and nonsusceptible antimicrobials in carbapenem-resistant Pseudomonas aeruginosa.
    Avery LM, Sutherland CA, Nicolau DP.
    J Med Microbiol; 2019 Jun 31; 68(6):893-897. PubMed ID: 31050629
    [Abstract] [Full Text] [Related]

  • 14. Bactericidal Effect of Tomatidine-Tobramycin Combination against Methicillin-Resistant Staphylococcus aureus and Pseudomonas aeruginosa Is Enhanced by Interspecific Small-Molecule Interactions.
    Boulanger S, Mitchell G, Bouarab K, Marsault É, Cantin A, Frost EH, Déziel E, Malouin F.
    Antimicrob Agents Chemother; 2015 Dec 31; 59(12):7458-64. PubMed ID: 26392496
    [Abstract] [Full Text] [Related]

  • 15. Antibacterial effect of seven days exposure to ceftolozane-tazobactam as monotherapy and in combination with fosfomycin or tobramycin against Pseudomonas aeruginosa with ceftolozane-tazobactam MICs at or above 4 mg/l in an in vitro pharmacokinetic model.
    Attwood M, Griffin P, Noel AR, Albur M, Macgowan AP.
    J Antimicrob Chemother; 2023 Sep 05; 78(9):2254-2262. PubMed ID: 37527369
    [Abstract] [Full Text] [Related]

  • 16. Synergistic activities of combinations of beta-lactams, fosfomycin, and tobramycin against Pseudomonas aeruginosa.
    Takahashi K, Kanno H.
    Antimicrob Agents Chemother; 1984 Nov 05; 26(5):789-91. PubMed ID: 6440482
    [Abstract] [Full Text] [Related]

  • 17. In vitro pharmacodynamics of fosfomycin against clinical isolates of Pseudomonas aeruginosa.
    Walsh CC, McIntosh MP, Peleg AY, Kirkpatrick CM, Bergen PJ.
    J Antimicrob Chemother; 2015 Nov 05; 70(11):3042-50. PubMed ID: 26209311
    [Abstract] [Full Text] [Related]

  • 18. Ticarcillin-tobramycin-rifampin: in vitro synergy of the triplet combination against Pseudomonas aeruginosa.
    Zuravleff JJ, Yu VL, Yee RB.
    J Lab Clin Med; 1983 Jun 05; 101(6):896-902. PubMed ID: 6406628
    [Abstract] [Full Text] [Related]

  • 19. The glycerol-3-phosphate permease GlpT is the only fosfomycin transporter in Pseudomonas aeruginosa.
    Castañeda-García A, Rodríguez-Rojas A, Guelfo JR, Blázquez J.
    J Bacteriol; 2009 Nov 05; 191(22):6968-74. PubMed ID: 19734311
    [Abstract] [Full Text] [Related]

  • 20. Synergistic activity of fosfomycin, β-lactams and peptidoglycan recycling inhibition against Pseudomonas aeruginosa.
    Hamou-Segarra M, Zamorano L, Vadlamani G, Chu M, Sanchez-Diener I, Juan C, Blazquez J, Hattie M, Stubbs KA, Mark BL, Oliver A.
    J Antimicrob Chemother; 2017 Feb 05; 72(2):448-454. PubMed ID: 27999022
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.